Editor's Pick
The 10-Year Treasury Yield has gone up a full percentage point, from a low of 3.6% in September 2024 to a level of 4.6%...
Hi, what are you looking for?
The market sometimes struggles to find direction, as it digests mixed yet impactful economic data. Wednesday was one of those days. With US 10-Year...
The 10-Year Treasury Yield has gone up a full percentage point, from a low of 3.6% in September 2024 to a level of 4.6%...
In this exclusive StockCharts video, Julius takes a look at what he recently called “The Best Five Sectors” on a relative rotation graph side-by-side...
Extremely heavy volume that accompanies a gap higher and a reversing candle after a lengthy uptrend is typically a sign of buyers’ exhaustion and...
The markets consolidated throughout the past week; the week was a shortened one with Monday, June 17th being a holiday on account of Bakri...
Last week, the broader market Indices hit another new high on Thursday before pulling back into Friday’s close. Not all areas participated, however, as...
In this StockCharts TV video, Mary Ellen reviews the broader markets, takes a close look at NVDA and other year-to-date winners that sold off last...
Moving averages are a crucial charting tool, but many of us aren’t getting the most out of them. In this edition of StockCharts TV‘s StockCharts in...
Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading leaked, or traders and investors...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish...
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL and SOXS,...
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets....
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated...